Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure

Matsumoto, Hiroki; Kasai, Takatoshi; Sato, Akira; Ishiwata, Sayaki; Yatsu, Shoichiro; Shitara, Jun; Murata, Azusa; Kato, Takao; Suda, Shoko; Matsue, Yuya; Hiki, Masaru; Takagi, Atsutoshi; Daida, Hiroyuki

doi:10.1007/s00380-019-01435-9

Cited by 48 publications

(38 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is an important index for the diagnosis and assessment of severe pulmonary infectious diseases [17]. Matsumoto's study also showed the value of CRP levels in severe pneumonia [18]. This study showed that CRP levels and the diameter of the largest lung lesion increased as the disease progressed.…”

Section: Discussionmentioning

confidence: 77%

C-reactive protein levels in the early stage of COVID-19

Wang¹

2020

Médecine et Maladies Infectieuses

596

471

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 77%

C-reactive protein levels in the early stage of COVID-19

Wang¹

2020

Médecine et Maladies Infectieuses

596

471

View full text Add to dashboard Cite

“…Increased levels of several inflammatory biomarkers, including cytokines such as IL-6, IL-2, IL-7, TNF-α, interferon (IFN)-γ, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, granulocytecolony stimulating factor (G-CSF), and CRP, procalcitonin (PCT), lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR) and ferritin, have been reported in COVID-19 patients. Among inflammatory biomarkers, CRP levels increase significantly at the early stage of the disease, and a positive correlation between increased CRP levels and disease severity has been described [13,20,33,34]. Tan et al [35] showed that CRP has good diagnostic accuracy in early predicting severe COVID-19 at a cut-off value of 20.42 mg/L (area under the curve [AUC] 0.87, 95% Confidence Interval [CI] 0.10-1.00, sensitivity and specificity 83% and 91%).…”

Section: Inflammationmentioning

confidence: 99%

Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19)

Ciaccio

Agnello

2020

Diagnosis

View full text Add to dashboard Cite

AbstractCoronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory disease, which can evolve into multi-organ failure (MOF), leading to death. Several biochemical alterations have been described in COVID-19 patients. To date, many biomarkers reflecting the main pathophysiological characteristics of the disease have been identified and associated with the risk of developing severe disease. Lymphopenia represents the hallmark of the disease, and it can be detected since the early stage of infection. Increased levels of several inflammatory biomarkers, including c-reactive protein, have been found in COVID-19 patients and associated with an increased risk of severe disease, which is characterised by the so-called “cytokine storm”. Also, the increase of cardiac and liver dysfunction biomarkers has been associated with poor outcome. In this review, we provide an overview of the main biochemical characteristics of COVID-19 and the associated biomarkers alterations.

show abstract

“…So, also C-reactive protein at admission is associated with in-hospital and long-term mortality. 7 But in our study, other than NT pro-BNP levels were not studied.…”

Section: Discussionmentioning

confidence: 77%

Predictors of In-Hospital Events for Patients with Nonischemic Acute Heart Failure

et al. 2019

View full text Add to dashboard Cite

Aim The main purpose of this article is to evaluate the clinical profile and in-hospital outcome among heart failure (HF) patients due to different diseases other than acute coronary syndromes (ACS) admitted in intensive coronary care unit (ICCU) at a tertiary center in South India. Materials and Methods This is an observational study of HF patients who were admitted to ICCU for a period of 6 months from January 2019 to June 2019. ACS patients were excluded. All the demographic data, clinical history, examination details, electrocardiographic (ECG), two-dimensional echocardiography (ECHO), baseline routine, and special investigations were collected. In-hospital progress of the patient was monitored along with events (recurrence of HF, arrhythmias, acute kidney injury, cardiogenic shock, and death). Results The total number of patients included in the study was 130. The male:female ratio was 2.09:1(88/42) with a mean age of 53.61 years. Hypertension and diabetes were present in 52.3% (68 patients). The etiology of HF was either ischemic (51 patients—39.2%) or dilated (24 patients—18.4%) cardiomyopathy in the majority of the patients (75 patients—57.6%). Rest of the diagnosis for HF were hypertrophic cardiomyopathy in 6 (4.6%) patients, chronic rheumatic heart disease in 18 (13.8%) patients, primary pulmonary arterial hypertension in 6 (4.6%) patients, severe valvular pulmonary restenosis in 3 (2.3%) patients, Cor-pulmonale in 6 (4.6%) patients, and others in 16 (12.3%) patients. Events occurred in 17 patients (13.1%). Mortality occurred in 6 patients (4.62%). Patients with events had more severe dyspnea with pedal edema with low systolic blood pressure clinically; all patients had ECG abnormalities with more severe left ventricular (LV) dilatation with right and LV dysfunction with significant functional mitral regurgitation (MR) with more laboratory abnormalities including grossly elevated N-terminal pro B-type natriuretic peptide (NT pro-BNP) levels when compared with patients without events. All the above said parameters were statistically significant (p < 0.05). Conclusion The common cause of HF admissions in ICCU was predominantly due to ischemic cardiomyopathy. Still, valvular heart diseases were accounting for 13.8% of admissions. High incidence of event rate (13.1%) despite the improvement in treatment strategies of ICCU patients in this new era, also the all-cause in-hospital mortality, was 4.62%. There were multiple clinical (degree of dyspnea, pedal edema, low systolic blood pressure), ECHO (LV dilatation with dysfunction, right ventricle dysfunction, significant MR), and laboratory parameters (pre-azotemia, anemia, thrombocytopenia, grossly elevated NT pro-BNP levels) to predict the in-hospital events.

show abstract

Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure

Cited by 48 publications

References 57 publications

C-reactive protein levels in the early stage of COVID-19

C-reactive protein levels in the early stage of COVID-19

Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19)

Predictors of In-Hospital Events for Patients with Nonischemic Acute Heart Failure

Contact Info

Product

Resources

About